|
|||||
|
|
Randomized clinical trial comparing the efficacy and safety of treatment with the once‐weekly dipeptidyl peptidase‐4 (DPP‐4) inhibitor omarigliptin or the once‐daily DPP‐4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy |
|
| Authors: | Ronald Goldenberg Ira Gantz Paula J. Andryuk BS Edward A. O'Neill Keith D. Kaufman Eseng Lai Yin Na Wang PhD Shailaja Suryawanshi Samuel S. Engel |
| Affiliation: | 1. LMC Diabetes & Endocrinology, Toronto, Ontario, Canada;2. Merck & Co., Inc., Kenilworth, New Jersey |
| Abstract: | |
| Keywords: | incretin therapy MK‐3102 oral antihyperglycaemic agent |